Renatus

Renatus is an early-stage biotech company dedicated to developing innovative therapies that directly target and reverse cellular cholesterol accumulation—a key hallmark of various age-related and metabolic diseases. The company's diverse pipeline encompasses a wide range of therapeutic areas, including chronic kidney disease, atherosclerosis, Alzheimer's disease, Niemann-Pick Type C disease, metabolic-associated steatohepatitis (MASH), and cancer. At the core of Renatus’s approach is the selective targeting of excess cholesterol, particularly within lysosomes, without disrupting cholesterol essential for normal cellular processes. This innovation addresses a critical challenge in cholesterol-targeting therapies: while cholesterol is vital for numerous physiological functions and is ubiquitous in cells, its abnormal accumulation in specific compartments, such as lysosomes, drives the progression of many diseases. Traditional cholesterol-targeting strategies often interfere with normal cholesterol functions, leading to significant adverse effects. Importantly, the removal of lysosomal cholesterol induces effects beyond simply lowering cholesterol levels. It reprograms key cellular pathways, including mitochondrial homeostasis, lipid synthesis and metabolism, inflammation regulation, and cell survival mechanisms. By addressing abnormal cholesterol accumulation, Renatus’s technology has the potential to improve cellular health, restore lipid metabolism, and transform the treatment landscape for diseases such as atherosclerosis, chronic kidney disease, Alzheimer's disease, and more.